Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env

Blood

Volumn 102, Issue 1, 2003, Pages 223-228

  Xin, Ke Qin ^b   Hoshino, Yuka ^b   Toda, Yoshihiko ^b   Igimi, Shizunobu ^b   Kojima, Yoshitsugu ^b   Jounai, Nao ^b   Ohba, Kenji ^b   Kushiro, Akira ^b   Kiwaki, Mayumi ^b   Hamajima, Kenji ^b   Klinman, Dennis ^b   Okuda, Kenji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENVELOPE GENE; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LACTOCOCCUS LACTIS; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; VACCINIA VIRUS; VIRUS ENVELOPE; VIRUS LOAD;

EID: 0038644449     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0110     Document Type: Article

References (37)

1. Bukawa H, Sekigawa K, Hamajima K, et al. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat Med. 1995;1:681-685.
2. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000;290:486-495.
3. Robinson H, Montefiori DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med. 1999;5:526-534.
4. Shiver JW, Fu T-M, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415:331-335.
5. Schnell MJ, Foley HD, Siler CA, McGettigan JP, Dietzachold B, Pomerantz RJ. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A. 2000;97:3544-3549.
6. Mandl CW, Aberle JH, Aberle SW, Holzmann H, Allison SL, Heinz FX. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat Med. 1996;4:1438-1440.
7. Matano T, Kano M, Odawa T, et al. Induction of protective immunity against pathogenic simian immunodeficiency virus by a foreign receptor-dependent replication of an engineered avirulent virus. Vaccine. 2000;18:3310-3318.
8. Caley IJ, Betts MR, Davis NL, Swanstrom R, Frelinger JA, Johnston RE. Venzuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine. 1999;17:3124-3135.
9. Xin K-Q, Urabe M, Yang J, et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to HIV. Hum Gene Ther. 2001;12:1047-1061.
10. Xin K-Q, Ooki T, Mizukami H, et al. Oral administration of recombinant adeno-associated virus elicits HIV-specific immune responses. Hum Gene Ther. 2002;13:1571-1581.
11. Aldovini A, Young RA. Humoral and cell-mediated immune response to live recombinant BCG-HIV vaccines. Nature. 1991;351:479-482.
12. Gruzza M, Fons M, Ouriet MF, Duval-Iflah Y, Ducluzeau R. Study of gene transfer in vitro and in the digestive tract of gnotobiotic mice from Lactococcus lactis strains to various strains belonging to human intestinal flora. Microb Releases. 1994;2:183-189.
13. Kliin N, Weerkamp AH, de Vos WM. Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl Environ Microbiol. 1995;61:2771-2774.
14. Robinson K, Chamberlain LM, Schofield KM, Wells JM, Page RWF. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol. 1997;15:653-657.
15. Gilbert C, Robinson K, Le Page RWF, Wells JM. Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis. Infect Immun. 2000;68:3251-3260.
16. Hirt H, Erlandsen SL, Dunny GM. Heterologous inducible expression of Enterococcus faecalis pCF10 aggregation substance Asc10 in Lactococcus lactis and Streptococcus gordonii contributes to cell hydrophobicity and adhesion to fibrin. J Bacteriol. 2000;182:2299-2306.
17. Kiwai M, Shimizu-Kadota M. Development of genetic manipulation systems and the application to genetic research in Lactobacillus casei strain shirota. Biosci Microflora. 2002;20:121-129.
18. Shirai M, Kozlowski S, Margulies DH, Berzofsky JA. Degenerate MHC restriction reveals the contribution of class I MHC molecules in determining the fine specificity of CTL recognition of an immunodominant determinant of HIV-1 gp160 V3 loop. J Immunol. 1997;158:3181-3188.
19. Belyakov IM, Derby MA, Ahlers JD, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A. 1998;95:1709-1714.
20. Behboudi S, Chao D, Klenerman P, Austyn J. The effects of DNA containing CpG motif on dendritic cells. Immunol. 2000;99:361-366.
21. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
22. Shen H, Miller JF, Fan X, Kolwyck D, Ahmed R, Harty JT. Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell. 1998;92:535-545.
23. Darji A, Guzman CA, Gerstel B, et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell. 1997;91:765-775.
24. + T cells and antiviral protective immunity. J Virol. 2001;75:9665-9670.
25. + T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine. 2002;20:623-629.
26. Friedman RS, Frankel FR, Xu Z, Lieberman J. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J Viol. 2000;74:9987-9993.
27. Jounai N, Okuda K, Kojiman Y, et al. Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV. J Gene Med. In press.
28. Vajdy M, Lycke N. Stimulation of antigen-specific T- and B-cell memory in local as well as systemic lymphoid tissues following oral immunization with cholera toxin adjuvant. Immunol. 1993;80:197-203.
29. Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM. Mucosal immunity: implications for vaccine development. Immunology. 1992;184:157-179.
30. Holmgren J, Lycke N, Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 1993;11:1179-1184.
31. Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infection as applied to vaccine development. Microbiol Rev. 1983;47:510-550.
32. Yamamoto S, Kiyono H, Yamamoto K, et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A. 1997;94:5267-5276.
33. Korber B, Brander C, Haynes B, et al. HIV molecular immunology. Available at: http:hiv-web.lanl.gov/content/immunology/maps/ct1/gp160.html. Accessed 2003.
34. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998;393:705-711.
35. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski JG, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393:648-659.
36. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
37. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature, 1998;392:245-252.